title: Multiple myeloma: progress in management aimed at improving QoL.
abstract: Despite the major recent strides achieved in myeloma treatment owing to the implementation of new anti-myeloma agents, bone destruction is still a leading cause of deterioration in quality of life (QoL) for affected patients. With improvement of survival, bone management will become more important for maintaining QoL especially in elderly patients; novel treatment modalities with bone anabolic activity are highly anticipated, as a means of restoring bone in bone destructive lesions as well as from the aspect of preventing bone destruction with currently available anti-resorptive agents. Long-term management of myeloma bone disease in the era of these new agents and a perspective on the development of new bone modifying agents will be discussed.
authors: Tokushima University Graduate School, Department of Hematology, Endocrinology and Metabolism Medicine and Bioregulatory Sciences.
authors: Masahiro
authors: M
authors: Abe
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001842:Bone and Bones / Q000378:metabolism; D015195:Drug Design; D006801:Humans; D009101:Multiple Myeloma / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D011788:Quality of Life
chemical_list: D050071:Bone Density Conservation Agents